Vivek V. Kamath has been appointed as the Chief Executive Officer at PlasmaGen BioSciences (P) Ltd, a leading player in the plasma-derived biopharmaceutical industry. Based in Bengaluru, Vivek will spearhead the company’s strategic vision, operational growth, and expansion into emerging healthcare markets. His appointment signals PlasmaGen’s commitment to advancing innovation and accessibility in critical care therapies.
With over two decades of leadership experience across the healthcare and life sciences sectors, Vivek brings a strong blend of business acumen, people leadership, and market expertise. Prior to this role, he served as Managing Director & General Manager at Abbott India Limited, where he led operations for both Abbott India and Abbott Specialty Care. Under his leadership, Abbott reinforced its leadership in key therapeutic categories, driving consistent revenue growth and strengthening brand trust among healthcare professionals and patients.
Beyond Abbott, Vivek has held significant advisory roles that reflect his influence across the healthcare investment and innovation ecosystem. He was Senior Advisor at TPG from 2024 to 2025 and Senior Advisor at Lighthouse Funds in 2025, where he guided portfolio strategies and supported high-impact healthcare ventures. His involvement in these roles highlights his strategic insight in fostering scalable, patient-centric business models.
Vivek is also passionate about leadership development and mentoring future business leaders. As a Lead Mentor at Crossmentors, he continues to guide professionals and entrepreneurs, helping them navigate complex business challenges and build resilient organizations. His mentorship style focuses on growth through empathy, innovation, and ethical leadership — qualities that have defined his career journey.
In his new capacity as CEO at PlasmaGen BioSciences, Vivek V. Kamath is expected to strengthen the company’s product portfolio, drive global collaborations, and accelerate the organization’s vision to deliver high-quality plasma-based therapies. His appointment comes at a pivotal time when the biopharmaceutical industry in India is evolving rapidly, and his leadership is poised to elevate PlasmaGen’s role as a key player in the healthcare value chain.